Affiliation:
1. Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
2. Beijing University of Chinese Medicine, Beijing, China
Abstract
Background:
Huangqi with the capacity to resist virus and preserve myocardium is a
potential herb for treating patients with COVID-19 and related myocardial injury.
Method:
We applied network pharmacology method and programming software including R and
Perl to explore the probable mechanism of Huangqi fighting against the disease. Ingredients and
target gene names of Huangqi were obtained from TCMSP database. Disease-associated genes
were mined by searching GeneCards database. Venny online software was applied to draw Venn
diagram of intersection genes. Cytoscape software was used to set up the network of disease, drug,
compounds and targets. STRING database was applied to set up protein protein interaction (PPI)
network. With intersection genes imported into WEBGESALT database, gene ontology (GO)
analysis was completed. An R script basing on Kyoto Encyclopedia of Genes and Genomes
(KEGG) database was applied to obtain KEGG pathways. Finally, we used AutoDockTools 1.5.6
software for molecular docking and PyMOL to visualize the docking details.
Results:
We obtained 20 active components and 18 potential target genes to construct a network,
and found out quercetin and kaempferol were core ingredients. Key targets included EGFR,
MAPK8, IL6, CASP3, RELA and PPARG. Huangqi showed its potential to reduce inflammatory
response to prevent cytokine storm by inhibiting EGFR, IL6 and MAPK and protect myocardium
by inhibiting apoptosis and oxidant stress. Huangqi may also work by adjusting ubiquitin and regulating
multiple viral pathways.
Conclusions:
Huangqi may play a therapeutic role in treating COVID-19 with myocardial injury
by the effects of resisting virus and protecting myocardium concurrently.
Publisher
Bentham Science Publishers Ltd.
Subject
Organic Chemistry,Computer Science Applications,Drug Discovery,General Medicine
Reference74 articles.
1. Turner A.J.; Hiscox J.A.; Hooper N.M.; ACE2: From vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 2004,25(6),291-294
2. Aghagoli G.; Gallo Marin B.; Soliman L.B.; Sellke F.W.; Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review. J Card Surg 2020,35(6),1302-1305
3. Huang C.; Wang Y.; Li X.; Ren L.; Zhao J.; Hu Y.; Zhang L.; Fan G.; Xu J.; Gu X.; Cheng Z.; Yu T.; Xia J.; Wei Y.; Wu W.; Xie X.; Yin W.; Li H.; Liu M.; Xiao Y.; Gao H.; Guo L.; Xie J.; Wang G.; Jiang R.; Gao Z.; Jin Q.; Wang J.; Cao B.; Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020,395(10223),497-506
4. Shi S.; Qin M.; Shen B.; Cai Y.; Liu T.; Yang F.; Gong W.; Liu X.; Liang J.; Zhao Q.; Huang H.; Yang B.; Huang C.; Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020
5. Tajbakhsh A.; Gheibi Hayat S.M.; Taghizadeh H.; Akbari A.; Inabadi M.; Savardashtaki A.; Johnston T.P.; Sahebkar A.; COVID-19 and cardiac injury: Clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther 2021,19(3),345-357
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献